DEF 14A: Revolution Medicines Announces 2024 Annual Meeting of Stockholders
Proxy Statement
Revolution Medicines will hold its 2024 Annual Meeting of Stockholders online on June 20, 2024, to vote on director elections, auditor ratification, and executive compensation.
Summary
- Revolution Medicines, Inc. is holding its 2024 Annual Meeting of Stockholders on June 20, 2024, at 7:30 a.m. Pacific Time, entirely online.
- Stockholders of record as of April 22, 2024, are eligible to vote on three proposals.
- The proposals include the election of three Class I directors, ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, and an advisory vote on executive compensation.
- The Board of Directors recommends voting FOR all director nominees, FOR the ratification of the auditor, and FOR the approval of the Say-on-Pay proposal.
- In 2023, the company's CEO's total compensation was approximately 31 times the median total compensation of all other employees.
- The median total compensation of all employees (excluding the CEO) was $330,751, while the CEO's total compensation was $10,411,247.
Sentiment
Score: 7
Explanation: The document is primarily informational and procedural, outlining the details of the upcoming annual meeting. The tone is professional and straightforward, with a positive outlook on corporate governance and executive compensation practices.
Positives
- The Board of Directors is actively engaged in corporate governance, with regular meetings and committees overseeing various aspects of the company's operations.
- The company has a Code of Business Conduct and Ethics in place, promoting ethical behavior among directors, officers, and employees.
- The Compensation Committee uses an independent consultant to ensure executive compensation is fair and competitive.
- Stockholders have the opportunity to provide feedback on executive compensation through the Say-on-Pay vote.
- The company has a clawback policy in place to recover erroneously awarded compensation.
Risks
- Failure to ratify the appointment of PricewaterhouseCoopers LLP could require the Audit Committee to reconsider its choice of independent auditor.
- An unfavorable advisory vote on executive compensation could lead to negative publicity and potential stockholder dissatisfaction.
- The company's success depends on its ability to attract and retain qualified executive officers and directors.
- The company's performance goals are subject to various risks and uncertainties, including clinical trial outcomes and regulatory approvals.
Future Outlook
The company will hold the next Say-on-Pay vote at the 2025 Annual Meeting of Stockholders, unless the Board decides to modify its policy regarding the frequency of soliciting Say-on-Pay Votes.
Management Comments
- Mark A. Goldsmith, M.D., Ph.D., Chair of the Board, Chief Executive Officer and President, expressed appreciation for stockholders' interest in Revolution Medicines.
- Management encourages stockholders to read the proxy statement and annual report and submit their proxy as soon as possible.
Industry Context
As a clinical-stage precision oncology company, Revolution Medicines operates in a competitive biotechnology and pharmaceutical landscape, requiring strong corporate governance and competitive executive compensation to attract and retain talent.
Comparison to Industry Standards
- The document mentions that the Compensation Committee reviews the compensation practices of peer companies to assess the competitiveness of compensation elements and overall compensation packages for its NEOs.
- The peer group includes companies like Alector Therapeutics, Allogene Therapeutics, Arcus Biosciences, Arvinas, Denali Therapeutics, Fate Therapeutics, ImmunoGen, Mirati Therapeutics, Relay Therapeutics, and Xencor.
- These companies are generally US-based, publicly traded biotechnology and pharmaceutical companies with clinical trials in Phases I, I/II, II and/or III and a market capitalization between 0.3 and 3.0 times Revolution Medicines' approximate market capitalization.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Amendment to Director Compensation Program | In March 2024, the Director Compensation Program was amended to (i) increase the annual cash retainer for the lead independent director to $30,000, (ii) reduce the size of the Initial Grant to an Initial Option to purchase 33,400 shares and 9,600 Initial RSUs and (iii) reduce the size of the Annual Grant to an Annual Option to purchase 16,700 shares and 4,800 Annual RSUs. | Date of Annual Meeting | The changes aim to better align director compensation with industry standards and incentivize continued service. |
Related Party Transactions
- The company has entered into indemnification agreements with each of its directors and executive officers.
- The Board has adopted a written related person transaction policy setting forth the policies and procedures for the review and approval or ratification of related person transactions.
Stakeholder Impact
- The outcome of the votes on the proposals will directly impact stockholders.
- Executive compensation decisions affect the company's ability to attract and retain key personnel.
- The selection of an independent auditor ensures the integrity of the company's financial reporting.
Next Steps
- Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
- The company will announce the voting results within four business days after the Annual Meeting via a Current Report on Form 8-K.
Key Dates
| Date | Description |
|---|---|
| April 22, 2024 | Record Date for determining stockholders eligible to vote at the Annual Meeting |
| April 25, 2024 | Date of Notice of Annual Meeting of Stockholders |
| April 29, 2024 | Approximate date of first mailing of the Notice of Internet Availability to stockholders of record |
| June 20, 2024 | Date of the Annual Meeting of Stockholders |
| December 30, 2024 | Deadline for stockholder proposals to be included in next year's proxy materials |
| February 20, 2025 | Start of the window for stockholders to present a proposal for next year's annual meeting |
| March 22, 2025 | End of the window for stockholders to present a proposal for next year's annual meeting |
| April 21, 2025 | Deadline for stockholders intending to solicit proxies in support of director nominees to provide notice |
Keywords
Annual Meeting, Proxy Statement, Stockholders, Board of Directors, Executive Compensation, Director Election, Auditor Ratification, Corporate Governance, PricewaterhouseCoopers, Say-on-Pay, Revolution Medicines
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.